• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

谷胱甘肽代谢相关基因特征可预测低级别胶质瘤的预后和治疗反应。

Glutathione metabolism-related gene signature predicts prognosis and treatment response in low-grade glioma.

机构信息

Department of Neurology, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.

Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.

出版信息

Aging (Albany NY). 2024 May 30;16(11):9518-9546. doi: 10.18632/aging.205881.

DOI:10.18632/aging.205881
PMID:38819225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11210255/
Abstract

Cancer cells can induce molecular changes that reshape cellular metabolism, creating specific vulnerabilities for targeted therapeutic interventions. Given the importance of reactive oxygen species (ROS) in tumor development and drug resistance, and the abundance of reduced glutathione (GSH) as the primary cellular antioxidant, we examined an integrated panel of 56 glutathione metabolism-related genes (GMRGs) across diverse cancer types. This analysis revealed a remarkable association between GMRGs and low-grade glioma (LGG) survival. Unsupervised clustering and a GMRGs-based risk score (GS) categorized LGG patients into two groups, linking elevated glutathione metabolism to poorer prognosis and treatment outcomes. Our GS model outperformed established clinical prognostic factors, acting as an independent prognostic factor. GS also exhibited correlations with pro-tumor M2 macrophage infiltration, upregulated immunosuppressive genes, and diminished responses to various cancer therapies. Experimental validation in glioma cell lines confirmed the critical role of glutathione metabolism in glioma cell proliferation and chemoresistance. Our findings highlight the presence of a unique metabolic susceptibility in LGG and introduce a novel GS system as a highly effective tool for predicting the prognosis of LGG.

摘要

癌细胞可以诱导分子变化，重塑细胞代谢，为靶向治疗干预创造特定的弱点。鉴于活性氧 (ROS) 在肿瘤发展和耐药性中的重要性，以及还原型谷胱甘肽 (GSH) 作为主要细胞抗氧化剂的丰富性，我们研究了不同癌症类型中 56 种谷胱甘肽代谢相关基因 (GMRG) 的综合面板。这项分析表明，GMRGs 与低级别胶质瘤 (LGG) 患者的生存之间存在显著关联。无监督聚类和基于 GMRGs 的风险评分 (GS) 将 LGG 患者分为两组，将较高的谷胱甘肽代谢与较差的预后和治疗结果联系起来。我们的 GS 模型优于既定的临床预后因素，是一个独立的预后因素。GS 还与促肿瘤 M2 巨噬细胞浸润、上调的免疫抑制基因以及对各种癌症治疗反应减弱相关。在神经胶质瘤细胞系中的实验验证证实了谷胱甘肽代谢在神经胶质瘤细胞增殖和化疗耐药性中的关键作用。我们的研究结果表明，LGG 中存在独特的代谢易感性，并提出了一种新的 GS 系统，作为预测 LGG 预后的高度有效工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/9bfb1d0ca4c9/aging-16-205881-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/7c940e4c5c9a/aging-16-205881-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/d1f33f7665b2/aging-16-205881-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/e87e0b2e37df/aging-16-205881-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/532bed00c1f6/aging-16-205881-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/7f93729b88e3/aging-16-205881-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/3698e564017a/aging-16-205881-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/e2329add852d/aging-16-205881-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/9bfb1d0ca4c9/aging-16-205881-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/7c940e4c5c9a/aging-16-205881-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/d1f33f7665b2/aging-16-205881-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/e87e0b2e37df/aging-16-205881-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/532bed00c1f6/aging-16-205881-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/7f93729b88e3/aging-16-205881-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/3698e564017a/aging-16-205881-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/e2329add852d/aging-16-205881-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e789/11210255/9bfb1d0ca4c9/aging-16-205881-g008.jpg

相似文献

1
Glutathione metabolism-related gene signature predicts prognosis and treatment response in low-grade glioma.谷胱甘肽代谢相关基因特征可预测低级别胶质瘤的预后和治疗反应。
Aging (Albany NY). 2024 May 30;16(11):9518-9546. doi: 10.18632/aging.205881.
2
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
3
Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.鉴定和验证与失巢凋亡相关的基因，以阐明低级别脑胶质瘤患者的预后和免疫机制。
Biochem Biophys Res Commun. 2024 Jun 4;711:149894. doi: 10.1016/j.bbrc.2024.149894. Epub 2024 Apr 5.
4
Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma.ARPC1A 在低级别胶质瘤进展中的预后相关性和验证。
Aging (Albany NY). 2024 Jun 19;16(14):11162-11184. doi: 10.18632/aging.205952.
5
A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.血小板衍生生长因子-DD 激活的自然杀伤细胞转录特征可预测低级别胶质瘤预后较好。
Front Immunol. 2021 Sep 2;12:668391. doi: 10.3389/fimmu.2021.668391. eCollection 2021.
6
Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.III 型胶原α 1 链受 GATA 结合蛋白 6 调控，影响低级别胶质瘤复发中的 II 型干扰素反应和丙酸盐代谢。
J Cell Mol Med. 2020 Sep;24(18):10803-10815. doi: 10.1111/jcmm.15705. Epub 2020 Aug 5.
7
Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.低级别胶质瘤中与缺氧相关的长链非编码 RNA 与预后和免疫微环境相关。
Front Immunol. 2021 Sep 30;12:731048. doi: 10.3389/fimmu.2021.731048. eCollection 2021.
8
An integrative analysis based on multiple cell death patterns identifies an immunosuppressive subtype and establishes a prognostic signature in lower-grade glioma.基于多种细胞死亡模式的综合分析确定了低级别神经胶质瘤中的一种免疫抑制亚型，并建立了一个预后标志物。
Ann Med. 2024 Dec;56(1):2412831. doi: 10.1080/07853890.2024.2412831. Epub 2024 Oct 10.
9
Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma.与低级别胶质瘤中 M2 巨噬细胞相关的显著恶性特征。
Front Immunol. 2021 Apr 16;12:659659. doi: 10.3389/fimmu.2021.659659. eCollection 2021.
10
A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.一个四蛋白表达预后标志物预测低级别胶质瘤的临床结局。
Gene. 2018 Dec 30;679:57-64. doi: 10.1016/j.gene.2018.08.001. Epub 2018 Aug 2.

本文引用的文献

1
Combination of bulk RNA sequencing and scRNA sequencing uncover the molecular characteristics of MAPK signaling in kidney renal clear cell carcinoma.批量RNA测序与单细胞RNA测序相结合揭示肾透明细胞癌中MAPK信号通路的分子特征。
Aging (Albany NY). 2024 Jan 12;16(2):1414-1439. doi: 10.18632/aging.205436.
2
Low-density lipoprotein receptor promotes crosstalk between cell stemness and tumor immune microenvironment in breast cancer: a large data-based multi-omics study.低密度脂蛋白受体促进乳腺癌中细胞干性与肿瘤免疫微环境的串扰：基于大数据的多组学研究。
J Transl Med. 2023 Nov 30;21(1):871. doi: 10.1186/s12967-023-04699-y.
3
A Nucleotide Metabolism-Related Gene Signature for Risk Stratification and Prognosis Prediction in Hepatocellular Carcinoma Based on an Integrated Transcriptomics and Metabolomics Approach.
基于整合转录组学和代谢组学方法的肝细胞癌风险分层和预后预测的核苷酸代谢相关基因特征
Metabolites. 2023 Oct 30;13(11):1116. doi: 10.3390/metabo13111116.
4
Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis.氧化还原模式在肿瘤免疫微环境中对自噬和凋亡的多方面作用。
Mol Cancer. 2023 Aug 10;22(1):130. doi: 10.1186/s12943-023-01831-w.
5
Identification of natural killer cell-related characteristics to predict the clinical prognosis and immune microenvironment of patients with low-grade glioma.鉴定自然杀伤细胞相关特征，以预测低级别脑胶质瘤患者的临床预后和免疫微环境。
Aging (Albany NY). 2023 Jul 5;15(13):6264-6291. doi: 10.18632/aging.204850.
6
Identification, and Experimental and Bioinformatics Validation of an Immune-Related Prognosis Gene Signature for Low-Grade Glioma Based on mRNAsi.基于mRNAsi的低级别胶质瘤免疫相关预后基因特征的鉴定、实验及生物信息学验证
Cancers (Basel). 2023 Jun 19;15(12):3238. doi: 10.3390/cancers15123238.
7
MGME1 associates with poor prognosis and is vital for cell proliferation in lower-grade glioma.MGME1 与不良预后相关，对低级别脑胶质瘤的细胞增殖至关重要。
Aging (Albany NY). 2023 May 8;15(9):3690-3714. doi: 10.18632/aging.204705.
8
Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.与免疫原性细胞死亡相关的分类可预测低级别胶质瘤的预后、免疫微环境特征和对免疫治疗的反应。
Front Immunol. 2023 Apr 19;14:1102094. doi: 10.3389/fimmu.2023.1102094. eCollection 2023.
9
Thirty years of progress in the management of low-grade gliomas.低级别胶质瘤治疗 30 年进展
Rev Neurol (Paris). 2023 Jun;179(5):425-429. doi: 10.1016/j.neurol.2023.03.001. Epub 2023 Apr 5.
10
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.低级别胶质瘤中的DNA甲基化与组蛋白修饰：当前认识与潜在临床靶点
Cancers (Basel). 2023 Feb 20;15(4):1342. doi: 10.3390/cancers15041342.